Topoisomerase I Inhibitors: Current Use and Prospects

摘要: Topoisomerase I inhibitors have wide applicability in oncology. Reproducible noncumulative toxicity, a known target and potential for combinations with other agents ensured their clinical role. c has been part of drug regimens ovarian cancer, small cell lung cancer (SCLC), the uterine cervix; it also used as radiosensitizer non-small (NSCLC). Irinotecan was second activity colon after failure many classes to build on long-established 5-fluorouracil-based regimens. prominent role treatment number gastrointestinal, pulmonary, gynecological, central nervous system cancers. Reasons individual selectivity are not readily apparent, pharmacology likely account differences toxicity efficacy among this family drugs. This overview provides glimpse at Top1 under development. Advances our understanding action covered elsewhere volume, reasons resistance will undoubtedly extend applications these